- Home
- VATE
VATE
INNOVATE Corp.
as 03-28-2025 2:44pm EST
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | N/A | IPO Year: | 1996 |
| Target Price: | N/A | AVG Volume (30 days): | 69.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.25 - $13.79 | Next Earning Date: | 05-06-2025 |
| Revenue: | $1,231,500,000 | Revenue Growth: | -16.30% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest INNOVATE Corp. News
VATE Breaking Stock News: Dive into VATE Ticker-Specific Updates for Smart Investing
Simply Wall St.
13 days ago
INNOVATE Insider Ups Holding By 25% During Year
GlobeNewswire
a month ago
INNOVATE Corp. to Report Fourth Quarter and Full Year 2024 Results on March 31st
GlobeNewswire
a month ago
MediBeacon® Transdermal GFR System receives device approval in China
Simply Wall St.
2 months ago
INNOVATE (NYSE:VATE) shareholders are up 114% this past week, but still in the red over the last three years
GuruFocus.com
2 months ago
Innovate Shares Surge 63% Following FDA Approval of MediBeacon's Kidney Function Assessment System
GlobeNewswire
2 months ago
MediBeacon® Transdermal GFR System Receives FDA Approval to Assess Kidney Function
GlobeNewswire
4 months ago
INNOVATE Corp. Portfolio Company R2 Technologies Announces Another Record-Breaking Quarter and Partnerships with Woodhouse Spas and Top Skincare Brands
Simply Wall St.
5 months ago
INNOVATE Third Quarter 2024 Earnings: US$1.18 loss per share (vs US$0.93 loss in 3Q 2023)
Compare VATE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VATE INNOVATE Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.